Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells
Authors
Keywords
-
Journal
MEDICAL ONCOLOGY
Volume 37, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-20
DOI
10.1007/s12032-020-01445-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression
- (2020) Changlin Li et al. CELLULAR ONCOLOGY
- Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer
- (2019) Changlin Li et al. PROSTATE
- Natural compound inducers of immunogenic cell death
- (2019) Marc Diederich ARCHIVES OF PHARMACAL RESEARCH
- Immunogenic cell death in cancer therapy: Present and emerging inducers
- (2019) Jingyi Zhou et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- eIF2α phosphorylation is pathognomonic for immunogenic cell death
- (2018) Lucillia Bezu et al. CELL DEATH AND DIFFERENTIATION
- Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer
- (2018) Gi-Hoon Nam et al. Nature Communications
- PKR and GCN2 stress kinases promote an ER stress-independent eIF2α phosphorylation responsible for calreticulin exposure in melanoma cells
- (2018) Paola Giglio et al. OncoImmunology
- eIF2α phosphorylation: A hallmark of immunogenic cell death
- (2018) Lucillia Bezu et al. OncoImmunology
- Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer
- (2018) Xiaohong Xia et al. Oncogenesis
- Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases
- (2018) Jianzhong Qin et al. JOURNAL OF SURGICAL RESEARCH
- A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
- (2017) Rahul Aggarwal et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Proteasome function shapes innate and adaptive immune responses
- (2016) Ilona Elisabeth Kammerl et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
- (2016) Chiara Pozzi et al. NATURE MEDICINE
- The miR-27a-calreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells
- (2016) T Colangelo et al. Cell Death & Disease
- Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis
- (2016) Changlin Li et al. Oncotarget
- Immunogenic cell death
- (2015) Abhishek D. Garg et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- The 26S proteasome is a multifaceted target for anti-cancer therapies
- (2015) Tatyana A. Grigoreva et al. Oncotarget
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells
- (2013) Jee-Eun Kim et al. PHARMACOLOGICAL RESEARCH
- MG132, a proteasome inhibitor, induces apoptosis in tumor cells
- (2012) Na GUO et al. Asia-Pacific Journal of Clinical Oncology
- The role of the proteasome in the generation of MHC class I ligands and immune responses
- (2011) E. J. A. M. Sijts et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
- (2011) F. Saad et al. CLINICAL CANCER RESEARCH
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now